Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial

Fig. 2

Tumor response to neoadjuvant therapy and follow-up. a Waterfall plot of tumor regression rates after neoadjuvant therapy based on pathology. b Swimmer plot showing treatment events and follow-up in the population of all included patients. PD-L1, programmed cell death-ligand 1, CPS, combined positive score; EBV, Epstein-Barr virus; MPR, major pathological response

Back to article page